Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
Seung Tae Kim, Won Jin Chang, Lihua Jin, Jae Sook Sung, Yun Ji Choi, Yeul Hong Kim
Cancer Res Treat. 2015;47(4):796-803. Published online 2015 Jan 30 DOI: https://doi.org/10.4143/crt.2014.106
Citations to this article as recorded by 
The Prognostic Utility of KRAS Mutations in Tissue and Circulating Tumour DNA in Colorectal Cancer Patients
Joel Petit, Georgia Carroll, Jie Zhao, Peter Pockney, Rodney J. Scott
Gastroenterology Insights.2024; 15(1): 107. CrossRef
Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer
Wei Chen, Jing-Lin Liang, Kai Zhou, Qing-Li Zeng, Jun-Wen Ye, Mei-Jin Huang
Cell Communication and Signaling.2020;[Epub] CrossRef
The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta‐analysis
Wenli Xie, Li Xie, Xianrang Song
Cancer Medicine.2019; 8(3): 1218. CrossRef
Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis
Linyan Chen, Yi Zhang, Yuan Cheng, Dan Zhang, Sha Zhu, Xuelei Ma
Gene.2018; 679: 328. CrossRef
The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis
Rongyuan Zhuang, Song Li, Qian Li, Xi Guo, Feng Shen, Hong Sun, Tianshu Liu, Alvaro Galli
PLOS ONE.2017; 12(8): e0182562. CrossRef